Next Article in Journal
The Hallmarks of Ageing in Human Immunodeficiency Virus Infection and the Impact of Antiretroviral Therapy on Telomeres: A Molecular Perspective
Previous Article in Journal
miR-27a rs895819 Polymorphism and Recurrent Pregnancy Loss in Caucasian Women: A Novel Genetic Risk Factor in a Challenging Fertility Dilemma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
CIMB
Volume 47
Issue 4
10.3390/cimb47040272
cimb-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Secondary Findings from Exome Sequencing of a Greek Cohort

by
Charilaos Kostoulas
1,
Athanasia Sesse
1,
Ioanna Bouba
1,
Spyridon Konitsiotis
2,
Sofia Markoula
2 and
Ioannis Georgiou
1,*
1
Laboratory of Medical Genetics in Clinical Practice, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece
2
Department of Neurology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece
*
Author to whom correspondence should be addressed.
Curr. Issues Mol. Biol. 2025, 47(4), 272; https://doi.org/10.3390/cimb47040272
Submission received: 13 March 2025 / Revised: 2 April 2025 / Accepted: 10 April 2025 / Published: 11 April 2025
(This article belongs to the Section Bioinformatics and Systems Biology)
Browse Figures
Versions Notes

Abstract

:
Exome sequencing (ES) is an essential part in clinical diagnosis of hereditary disorders. However, ES can reveal secondary findings (SFs) in medically actionable genes that are not related to the patient’s phenotype. In this study, we performed ES to 280 unrelated individuals of a Greek cohort and calculated the frequency of SFs in 81 ACMG SF v3.2 genes. Variants were classified using the standards and guidelines established by the American College of Medical Genetics and Genomics (ACMG). We identified 12 individuals (4.3%) who carried a pathogenic (P)/likely pathogenic (LP) variant in genes associated with dominant disorders. The variants were found in genes BRCA1, BRCA2, MSH6, LDLR, MYH7, and TTN. Notably, we discovered a P founder variant for the Greek population and one P variant with high prevalence in BRCA1 gene. Additionally, we observed a high prevalence of P/LP variants in the LDLR gene. In conclusion, this is the first study that calculates the prevalence of P/LP variants in the ACMG actionable gene list for SFs in Greece. The results of our study could serve as a guide for the national carrier screening program and may contribute to the precise treatment of certain human disorders.

1. Introduction

Over the last two decades, technological advances in Next-Generation Sequencing (NGS) have led to a decline in the sequencing cost and an increase in the amount of sequencing data produced. Exome sequencing (ES) and genome sequencing (GS) have become crucial for research purposes and clinical diagnosis. ES is particularly used to identify variants which cause complex and rare hereditary disorders. ES produces a huge number of variants, some of which are associated with the disorder for which the patient was referred [1]. However, with ES, variants called secondary findings (SFs) or incidental findings (IFs), in medically actionable genes unrelated to the patient’s disorder, can also be detected.
The American College of Medical Genetics and Genomics (ACMG) has proposed recommendations for reporting SFs in clinical ES or GS. Initially, in 2013, the ACMG released a list of 56 genes, known to be medically actionable, associated with 27 medical conditions [2]. In 2015, the list was updated to 59 genes and 27 conditions in ACMG SF v.2.0 [3]. The last versions of the ACMG lists are listed as ACMG SF v.3.0, ACMG CF v.3.1 and ACMG SF v.3.2, which contain 73 genes, 78 genes, and 81 genes, respectively [4,5,6]. These genes are associated with cardiovascular, cancer, metabolic, and miscellaneous disorders.
Furthermore, ACMG and the Association for Molecular Pathology (AMP) released 28 criteria for the interpretation of sequence variants. These criteria are applicable to many genes and disorders with different hereditary patterns. According to the ACMG guidelines, two pathogenic (P) or likely pathogenic (LP) variants in ACMG SF v3.2 genes associated with autosomal recessive (AR) inheritance, one variant in genes associated with dominant inheritance and at least one variant in ACMG SF v3.2 genes associated with X-linked (XL) disorders should be reported [6].
In this study, we calculated the frequencies of SFs in medically actionable ACMG v3.2 genes, as well as the carrier rate and the at-risk couple rates for genes associated with recessive disorders. The SFs were drawn from a regional Greek cohort of 280 unrelated patients, who were referred for rare disorder diagnosis. The aim of our study was to identify—through ES—the frequency of SFs of 81 genes and to determine the most common P/LP variants in the Greek population. To the best of our knowledge, this is the first retrospective study for SFs conducted in Greece.

2. Materials and Methods

A total of 280 individuals, initially referred for rare disorder testing, were enrolled in this study. Clinical and demographic information was collected and written informed consent was obtained from all participants or their legal guardians. The primary indications for referral included neurological disorders (33.2%), nephrological diseases (30%), metabolic disorders (18.6%), endocrine disorders (3.9%), hematologic conditions (3.2%), eye disorders (1.5%), cardiovascular diseases (0.7%), and other conditions (8.9%) (Figure 1).
Peripheral blood samples were collected from each participant and genomic DNA was extracted from EDTA blood leukocytes using the NucleoSpin Blood kit, Macherey-Nagel, Dueren, Germany. Whole-Exome Sequencing (WES) was performed using the DNA Prep Exome2.0 Plus Enrichment and Mitochondrial DNA, Illumina, following the manufacturer’s recommendations. Prepared DNA libraries were sequenced on NextSeq 1000, Illumina, San Diego, CA, USA. WES data quality control standards included a mean depth of coverage >100×, with >98% regions at 20×. Variant calling was performed using the Genome Analysis Toolkit (GATK) version 4.5.0.0 and selected variants were filtered using a minor allele frequency (MAF) of <1%.
Variant interpretation was carried out using the Franklin by Genoox version 82 software and was limited to the 81 clinically actionable genes recommended by the ACMG in the SF v3.2 list (Supplementary Table S1) [6]. The list included 28 genes related to cancer phenotypes (27 autosomal dominant (AD) and 1 AR), 40 genes associated with cardiovascular phenotypes (38 AD and 2 AR), 4 genes associated with inborn errors of metabolism (IEM) phenotypes (2 AR and 2 XL), and 9 genes related to miscellaneous phenotypes (6 AD and 3 AR) (Figure 2). The same analysis was also performed using the ACMG SF v2.0 (59 genes—Supplementary Table S2, Figure 3) and v3.0 (73 genes—Supplementary Table S3, Figure 3) lists in order to assess the yield across different versions [3,4]. It is noted that none of the individuals have a genetic diagnosis associated with any of these genes.
Variants were classified using the standards and guidelines established by the ACMG, and only P or LP variants were included in the analysis [7]. In particular, variants that were previously reported in genomic databases (i.e., ClinVar, ClinGen, LOVD) or the literature and classified as P/LP, as well as novel nonsense, frameshift, and splice site variants classified as P/LP and predicted to cause the disorder or variants with a pLoF (predicted loss-of-function) annotation in genes, where loss-of-function is a known cause of disease, were considered medically actionable and included in the study.
For AR or XL conditions, at-risk couple rates were also calculated. The at-risk couple rate is the probability that both partners are carriers of a P or LP variant in the same gene (AR conditions), or the female is carrier of a P or LP variant (XL conditions). For AR conditions, the at-risk couple rate is defined as the gene’s (or condition’s) carrier rate squared, while for XL conditions it is defined as the gene (condition) carrier rate [8,9].

3. Results

3.1. Population Demographics

A total of 280 individuals participated in the study; 169 (60%) were children and adolescents (<18 years old), while 111 (40%) were over the age of 18 at the time of testing. The mean ± SD age was 21.3 ± 19.6 years. Amongst those individuals, 133 (47.5%) were females and 147 (52.5%) were males (Figure 4). According to the demographic characteristics, the cohort consisted exclusively of individuals from a particular Greek region (northwestern Greece—Epirus).

3.2. SFs Analysis

A total of 10,258 non-silent variants (single nucleotide variants—SNVs, and INDELs) were detected in the 81 ACMG-recommended genes in WES of 280 individuals [6]. For each participant, there were on average 36.6 non-silent variants. Following the ACMG variant classification standards and guidelines, 28 variants were classified as P or LP in 23 individuals (8.2%) when 81 gene approach was used (Figure 5, Supplementary Table S4) [7]. Specifically, those variants were either reported previously in the ClinVar database as causative variants of associated diseases or were novel but were classified as P/LP by ACMG criteria and could cause premature termination of the codon in a loss-of-function mechanism gene (including nonsense, frameshift, and canonical splice site variants). In addition, percentages of SF in the 59 ACMG genes (v2.0) were also calculated, resulting in a yield of 6.8% (19 carriers, 24 variants) [3]. When the percentage of SF in 73 genes (v3.0) was calculated, a yield of 8.2% was obtained (23 individuals, 28 variants) [4]. Number of carriers and variants in 59, 73, and 81 ACMG genes are presented in Table 1.

3.2.1. Dominant Actionable Genes

Amongst the 280 individuals who were screened, 12 (4.3%) had one medically actionable variant. Furthermore, 9 of the different variants were related to 6 out of the 71 dominant actionable genes (Table 2). Two of those variants were detected in more than one individual.
Eight variants in three genes associated with cardiovascular phenotypes were found in eight individuals, thus constituting 66.7% of the individuals with SFs in dominant actionable genes and 2.9% of the entire study group. There were 5 men, representing 3.4% of the 147 males in the study, and 3 were women, representing 2.3% of the 133 females. The most frequent gene was LDLR (six carriers), which is associated with familial hypercholesterolemia [10,11]. Three different variants were identified in LDLR, with the c.858C>A (p.Ser286Arg) variant detected in three participants, while the c.1775G>A (p.Gly592Glu) variant was detected in two participants. Furthermore, c.2609G>T p.(Arg870Leu) and c.52903C>T p.(Arg17635*) were identified in MYH7 (associated with hypertrophic cardiomyopathy) and TTN (associated with dilated cardiomyopathys), respectively (Table 2) [12,13,14,15].
Variants related to cancer phenotypes were detected in four participants, thus constituting 33.3% of the individuals with SFs in dominant actionable genes and 1.4% of the entire cohort. Three participants out of five were men, representing 2.0% of the males in this study, while one was female (0.8% of the females). The most frequent gene was BRCA1 with two variants in two individuals (one male and one female) (Table 2). This gene is associated with increased susceptibility to breast and ovarian cancer [16,17,18]. Medically actionable variants were also identified in two other cancer-related genes, including BRCA2 and MSH6, which are associated with hereditary breast and/or ovarian cancer and Lynch syndrome, respectively (Table 1) [16,17,18,19,20].
None of the 280 participants carried a variant of any dominant actionable gene related to IEMs or miscellaneous phenotypes.

3.2.2. Recessive Actionable Genes

In addition to dominant disease alleles, 15 individuals (5.4%) were also identified to be carriers of at least one disease allele in four of the eight recessive actionable genes, with 1 participant carrying two alleles for two recessive disorders. A total of 16 ACMG SF variants, of which 5 were unique, were detected when the 81 gene approach was used (Table 3). Four carriers of a heterozygous recessive high-risk disease allele also had a dominant high-risk disease allele (Supplementary Table S4).
P/LP variants in a gene predisposed to hereditary cancer were most frequently observed. More specifically, the c.1103G>A (p.Gly368Asp) variant in the MUTYH gene was found in eight individuals, constituting 53.3% of the subjects with SFs in recessive medical actionable genes and 2.9% of the entire cohort (Table 3). There were 5 female carriers, representing 3.8% of the 133 women in the study, and 3 were male, representing 2.0% of the 147 men. MUTYH is related to MUTYH-associated polyposis (MAP) [21,22].
Five variants in two genes (HFE, ATP7B) in the miscellaneous phenotype category were identified in four individuals (26.7% of the individuals with SFs in recessive actionable genes, 1.4% of the entire study group—two male, two female). Two of those variants were unique (Table 3). The c.845G>A (p.Cys282Tyr) variant in the HFE gene, responsible for hereditary hemochromatosis, was the most common (4 carriers), while the c.2304dup (p.Met769Hisfs*26) variant in the ATP7B gene was identified in one individual [23,24]. The ATP7B gene is associated with Wilson disease [25,26]. In addition, there was one participant carrying two variants for two different miscellaneous recessive disease-associated genes. As a result, HFE c.8445G>A (p.Cys282Tyr) and ATP7B c.2304dup (p.Met769Hisfs*26) variants were detected in the same case (Supplementary Table S4).
The medically actionable variants associated with IEM phenotypes were detected in three individuals, representing 20.0% of the individuals with SFs in recessive genes and 1.1% of our cohort. Amongst these three individuals, there were two men and one woman. In total, two different variants were identified in the GAA gene: c.-32-13T>G in two individuals, and c.1465G>A (p.Asp489Asn) in one individual. The GAA gene is associated with Pompe disease (Table 3) [27,28].
Finally, the at-risk couple rates as well as the carrier rates of the four recessive actionable genes that were detected in our cohort are listed in Table 4.
It is noted that none of the 15 individuals—with variants in genes associated with AR conditions—carried homozygous or compound heterozygous recessive disease alleles. According to the ACMG guidelines for reporting SFs, a single variant in genes linked to recessively inherited phenotypes does not meet the criteria for reporting [6].

4. Discussion

In this study, we performed ES to investigate the frequency of genetic variants in the ACMG actionable gene list v3.2 in a patient cohort in Northwestern Greece [6]. Amongst 280 patients, who were referred for a genetic disorder other than the ones included in the ACMG disorder list, we identified 23 individuals carrying at least one variant of the 81 ACMG SF v3.2 recommended genes. The carrier frequency of all the variants was 8.2% in the ACMG gene list. Also, in our study, the prevalence of SFs in the ACMG SF v2.0 and v3.0 gene lists was 6.8% and 8.2%, respectively [3,4].
Furthermore, in our cohort, 12 individuals were carriers of one P or LP variant in one of the 71 medically actionable genes associated with a dominant inherited disorder, and no patient carried two variants within a gene associated with recessive inherited disorder. In our study, we obtained a yield of 4.3%, which is consistent with other studies that estimated a carrier frequency range of 2.5 to 5% [29,30,31]. A Serbian cohort study of 443 participants reported a frequency of 3.8% in 81 ACMG SF v3.2 actionable genes [32]. Also, a study from China reported a carrier frequency of 5.3% and a study for the Icelandic population found a frequency of 4% in 73 ACMG SF v3.0 genes [33,34].
The findings of our study showed common variations in the Mediterranean population. More specifically, a study on Italians found the c.1187G>A p.(Gly396Asp) and c.1775G>A p.(Gly592Glu) variants in the MUTYH and LDLR genes, respectively, at a high frequency, similar to what was revealed in our study [35]. As is well known from previous studies on Mediterranean populations, many variants of thalassemia came from Greece and especially from Northwestern Greece [36,37].
However, our results are not in line with other studies. Two studies involving 21,915 and 1303 individuals reported a carrier frequency of 2.54% and 2.5%, respectively, in the 56 ACMG SF v2.0 gene list [38,39]. The major reason for these differences is the use of different versions of the ACMG gene lists, which leads to disparities in the number of genes analyzed. The wide range of the observed prevalence between the studies is very common and can depend on several factors, such as the NGS technology used as well as the classification of assessed variants. Finally, another reason for the difference in the observed prevalence in our study—in comparison to other studies—is the smaller number of participants in our research versus previous ones [39].
In our study, all participants opted to receive SFs as part of their WES analysis. This decision reflects an active choice to receive additional genetic information in line with the ACMG guidelines for reporting SFs. It is worth noting that other studies, such as one by Brunfeldt et al., have explored the decision-making process regarding SFs, specifically examining factors like sex, age, and country. These studies provide valuable insights into how demographic variables may influence patients’ and families’ decisions to opt in for secondary findings [40]. Additionally, in the same study, it was reported that out of patients who opted in, a SF was detected in 2.7% of the cases.
In our study, we identified eight variants in genes causing cardiac disorders. One individual was a carrier (1/280) of the missense c.2609G>T p.(Arg870Leu) variant in the MYH7 gene, which has been reported as a P variant for hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy is a common disorder, with its frequency in the general population estimated to be between one in 500 and one in 3000 [41]. Furthermore, in the TTN gene, we included only the variant c.52903C>T p.(Arg17635*), as the ACMG guidelines recommend that only frameshift and nonsense variants should be reported in the TTN gene.
In our sample, we found six individuals with familial hypercholesterolemia carrying a P or LP variant in the LDLR gene. The large number of individuals with familial hypercholesterolemia is common in the Northwestern Greece region and this could explain the high prevalence of pathogenic variants in LDLR observed in our study. The three variants that have been identified are common in Northwestern Greece and show a regional distribution [42,43]. More specifically, the two most common variants, c.858C>A p.(Ser286Arg) and c.1775G>A p.(Gly592Glu), were found in three and two individuals, respectively, and may be considered founder mutations. Furthermore, familial hypercholesterolemia is often underdiagnosed, which may contribute to an underestimated prevalence [44,45,46].
Additionally, we identified four individuals who carried variants in cancer predisposition genes. More specifically, the following variants have been identified: c.5497G>A p.(Val1833Met) and c.3700_3704del p.(Val1234Glnfs*8)—which are a well-known founder variant and P variant with high prevalence, respectively, in the Greek population—in the BRCA1 gene in two individuals; c.8169T>A p.(Asp2723Glu) in the BRCA2 gene and c.2653A>T p.(Lys885*) in the MSH6 gene in the other two individuals [47,48]. The two BRCA1 variants should be included in a potential national carrier screening program for breast and ovarian cancer, as early detection of breast cancer may lead to decreased morbidity with improved cancer outcomes [49].
Furthermore, in our study, we identified that 5.4% of the patients in our cohort were carriers of at least one P/LP variant in the ATP7B, GAA, HFE, and MUTYH genes, which are associated with recessive disorders. In the GAA gene, we identified three individuals who were carriers of two variants. In the HFE gene, four individuals were carriers of one variant while in the MUTYH gene, eight individuals were found to be carriers of one variant. Our results suggest that the presence of two specific variants in the MUTYH and HFE genes could be characterized as founder mutations for Northwestern Greece. However, according to the ACMG guidelines, a heterozygous variant in a recessive-associated gene should not be reported, it might be beneficial to consider the high carrier frequency of P/LP variants and the high at-risk couple rate, especially in specific population groups (such as Northwestern Greece) with notable susceptibility. The high prevalence of carrier status for these four genes could be very valuable for specific populations with a high rate of consanguinity.
The results of our study indicate that certain disorders—such as familial hypercholesterolemia—occur more frequently in Northwestern Greece and they are indeed underdiagnosed. Genetic testing should be conducted even in patients classified as having “unlikely” or “possible” familial hypercholesterolemia, based on the Dutch criteria, as familial hypercholesterolemia could not be ruled out in these cases [50]. Additionally, cascade screening and/or reverse cascade screening should be integrated to improve detection and diagnosis [51].
In summary, this is the first study that estimates the prevalence of SF variants in Greece based on the ACMG SF v3.2 gene list. We identified the prevalence of 4.3% of patients who carry a P or LP variant in a medically actionable gene and who have an increased risk of developing a severe genetic disorder. The results of our project could serve as a guide for the national carrier screening program, which is already implemented in Greece for specific disorders. The data may contribute to the prevention and precise treatment of certain human disorders.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cimb47040272/s1.

Author Contributions

Conceptualization, C.K., I.B. and I.G.; methodology, C.K., A.S., I.B. and I.G.; software, C.K., A.S. and I.B.; validation, C.K., A.S. and I.B.; formal analysis, C.K. and A.S.; investigation, C.K., A.S., I.B. and I.G.; resources, I.B. and I.G.; data curation, S.K., C.K., A.S. and S.M.; writing—original draft preparation, C.K. and A.S.; writing—review and editing, C.K., A.S., I.B., S.M. and I.G.; visualization, S.M., S.K. and I.G.; supervision, I.G.; project administration, C.K., I.B. and I.G.; funding acquisition, I.B. and I.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University of Ioannina (protocol code 6531/2025).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
ACMGAmerican College of Medical Genetics and Genomics
ADAutosomal Dominant
AMPAssociation for Molecular Pathology
ARAutosomal Recessive
ESExome Sequencing
GATKGenome Analysis Toolkit
GSGenome Sequencing
IEMInborn Errors of Metabolism
IFIncidental Finding
LPLikely Pathogenic
MAFMinor Allele Frequency
NGSNext-Generation Sequencing
PPathogenic
pLoFPredicted Loss-of-Function
SFSecondary Finding
SNVSingle Nucleotide Variant
WESWhole-Exome Sequencing
XLX-Linked

References

  1. Tang, C.S.; Dattani, S.; So, M.; Cherny, S.S.; Tam, P.K.H.; Sham, P.C.; Garcia-Barcelo, M.-M. Actionable Secondary Findings from Whole-Genome Sequencing of 954 East Asians. Hum. Genet. 2018, 137, 31–37. [Google Scholar] [CrossRef] [PubMed]
  2. Green, R.C.; Berg, J.S.; Grody, W.W.; Kalia, S.S.; Korf, B.R.; Martin, C.L.; McGuire, A.L.; Nussbaum, R.L.; O’Daniel, J.M.; Ormond, K.E.; et al. ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing. Genet. Med. 2013, 15, 565–574. [Google Scholar] [CrossRef] [PubMed]
  3. Kalia, S.S.; Adelman, K.; Bale, S.J.; Chung, W.K.; Eng, C.; Evans, J.P.; Herman, G.E.; Hufnagel, S.B.; Klein, T.E.; Korf, B.R.; et al. Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update (ACMG SF v2.0): A Policy Statement of the American College of Medical Genetics and Genomics. Genet. Med. 2017, 19, 249–255. [Google Scholar] [CrossRef] [PubMed]
  4. Miller, D.T.; Lee, K.; Chung, W.K.; Gordon, A.S.; Herman, G.E.; Klein, T.E.; Stewart, D.R.; Amendola, L.M.; Adelman, K.; Bale, S.J.; et al. ACMG SF v3.0 List for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing: A Policy Statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 2021, 23, 1381–1390. [Google Scholar] [CrossRef]
  5. Miller, D.T.; Lee, K.; Abul-Husn, N.S.; Amendola, L.M.; Brothers, K.; Chung, W.K.; Gollob, M.H.; Gordon, A.S.; Harrison, S.M.; Hershberger, R.E.; et al. ACMG SF v3.1 List for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing: A Policy Statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 2022, 24, 1407–1414. [Google Scholar] [CrossRef]
  6. Miller, D.T.; Lee, K.; Abul-Husn, N.S.; Amendola, L.M.; Brothers, K.; Chung, W.K.; Gollob, M.H.; Gordon, A.S.; Harrison, S.M.; Hershberger, R.E.; et al. ACMG SF v3.2 List for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing: A Policy Statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 2023, 25, 100866. [Google Scholar] [CrossRef]
  7. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [Google Scholar] [CrossRef]
  8. Ben-Shachar, R.; Svenson, A.; Goldberg, J.D.; Muzzey, D. A Data-Driven Evaluation of the Size and Content of Expanded Carrier Screening Panels. Genet. Med. 2019, 21, 1931–1939. [Google Scholar] [CrossRef]
  9. Guo, M.H.; Gregg, A.R. Estimating Yields of Prenatal Carrier Screening and Implications for Design of Expanded Carrier Screening Panels. Genet. Med. 2019, 21, 1940–1947. [Google Scholar] [CrossRef]
  10. Abifadel, M.; Boileau, C. Genetic and Molecular Architecture of Familial Hypercholesterolemia. J. Intern. Med. 2023, 293, 144–165. [Google Scholar] [CrossRef]
  11. Xiang, Z.; Li, J.-R.; Wan, W.-M.; Li, S.-H.; Wu, J. Familial Hypercholesterolemia: Current Limitations and Future Breakthroughs. World J. Exp. Med. 2024, 14, 99968. [Google Scholar] [CrossRef] [PubMed]
  12. Akhtar, M.M.; Lorenzini, M.; Cicerchia, M.; Ochoa, J.P.; Hey, T.M.; Sabater Molina, M.; Restrepo-Cordoba, M.A.; Dal Ferro, M.; Stolfo, D.; Johnson, R.; et al. Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circ. Heart Fail. 2020, 13, e006832. [Google Scholar] [CrossRef] [PubMed]
  13. Chen, S.N.; Mestroni, L.; Taylor, M.R.G. Genetics of Dilated Cardiomyopathy. Curr. Opin. Cardiol. 2021, 36, 288–294. [Google Scholar] [CrossRef] [PubMed]
  14. Marian, A.J. Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Circ. Res. 2021, 128, 1533–1553. [Google Scholar] [CrossRef]
  15. Gao, Y.; Peng, L.; Zhao, C. MYH7 in Cardiomyopathy and Skeletal Muscle Myopathy. Mol. Cell Biochem. 2024, 479, 393–417. [Google Scholar] [CrossRef]
  16. Jayson, G.C.; Kohn, E.C.; Kitchener, H.C.; Ledermann, J.A. Ovarian Cancer. Lancet 2014, 384, 1376–1388. [Google Scholar] [CrossRef]
  17. Loibl, S.; Poortmans, P.; Morrow, M.; Denkert, C.; Curigliano, G. Breast Cancer. Lancet 2021, 397, 1750–1769. [Google Scholar] [CrossRef]
  18. Lee, Y.-C.; Lee, Y.-L.; Li, C.-Y. BRCA Genes and Related Cancers: A Meta-Analysis from Epidemiological Cohort Studies. Medicina 2021, 57, 905. [Google Scholar] [CrossRef]
  19. Cerretelli, G.; Ager, A.; Arends, M.J.; Frayling, I.M. Molecular Pathology of Lynch Syndrome. J. Pathol. 2020, 250, 518–531. [Google Scholar] [CrossRef]
  20. Ene, C.V.; Bulai, C.T.L.A.; Geavlete, P.; Popescu, R.I.; Vacaroiu, I.A.; Georgescu, D.E.; Isaconi, I.V.; da Lina Andreea Munteanu, M.; Ene, C.D.; Militaru, A.; et al. New Insights into Lynch Syndrome: A Narrative Review. Chirurgia 2023, 118, 584–595. [Google Scholar] [CrossRef]
  21. Ma, H.; Brosens, L.A.A.; Offerhaus, G.J.A.; Giardiello, F.M.; de Leng, W.W.J.; Montgomery, E.A. Pathology and Genetics of Hereditary Colorectal Cancer. Pathology 2018, 50, 49–59. [Google Scholar] [CrossRef] [PubMed]
  22. Aelvoet, A.S.; Buttitta, F.; Ricciardiello, L.; Dekker, E. Management of Familial Adenomatous Polyposis and MUTYH-Associated Polyposis; New Insights. Best Pract. Res. Clin. Gastroenterol. 2022, 58–59, 101793. [Google Scholar] [CrossRef] [PubMed]
  23. Gerhard, G.S.; Paynton, B.V.; DiStefano, J.K. Identification of Genes for Hereditary Hemochromatosis. Methods Mol. Biol. 2018, 1706, 353–365. [Google Scholar] [CrossRef] [PubMed]
  24. Katsarou, M.-S.; Papasavva, M.; Latsi, R.; Drakoulis, N. Hemochromatosis: Hereditary Hemochromatosis and HFE Gene. Vitam. Horm. 2019, 110, 201–222. [Google Scholar] [CrossRef]
  25. Członkowska, A.; Litwin, T.; Dusek, P.; Ferenci, P.; Lutsenko, S.; Medici, V.; Rybakowski, J.K.; Weiss, K.H.; Schilsky, M.L. Wilson Disease. Nat. Rev. Dis. Primers 2018, 4, 21. [Google Scholar] [CrossRef]
  26. Mulligan, C.; Bronstein, J.M. Wilson Disease: An Overview and Approach to Management. Neurol. Clin. 2020, 38, 417–432. [Google Scholar] [CrossRef]
  27. Taverna, S.; Cammarata, G.; Colomba, P.; Sciarrino, S.; Zizzo, C.; Francofonte, D.; Zora, M.; Scalia, S.; Brando, C.; Curto, A.L.; et al. Pompe Disease: Pathogenesis, Molecular Genetics and Diagnosis. Aging 2020, 12, 15856–15874. [Google Scholar] [CrossRef]
  28. Davison, J.E. Advances in Diagnosis and Management of Pompe Disease. J. Mother Child 2020, 24, 3–8. [Google Scholar] [CrossRef]
  29. Dorschner, M.O.; Amendola, L.M.; Turner, E.H.; Robertson, P.D.; Shirts, B.H.; Gallego, C.J.; Bennett, R.L.; Jones, K.L.; Tokita, M.J.; Bennett, J.T.; et al. Actionable, Pathogenic Incidental Findings in 1,000 Participants’ Exomes. Am. J. Hum. Genet. 2013, 93, 631–640. [Google Scholar] [CrossRef]
  30. Amendola, L.M.; Dorschner, M.O.; Robertson, P.D.; Salama, J.S.; Hart, R.; Shirts, B.H.; Murray, M.L.; Tokita, M.J.; Gallego, C.J.; Kim, D.S.; et al. Actionable Exomic Incidental Findings in 6503 Participants: Challenges of Variant Classification. Genome Res. 2015, 25, 305–315. [Google Scholar] [CrossRef]
  31. Maxwell, K.N.; Hart, S.N.; Vijai, J.; Schrader, K.A.; Slavin, T.P.; Thomas, T.; Wubbenhorst, B.; Ravichandran, V.; Moore, R.M.; Hu, C.; et al. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. Am. J. Hum. Genet. 2016, 98, 801–817. [Google Scholar] [CrossRef] [PubMed]
  32. Branković, M.; Han, H.; Janković, M.; Marjanović, A.; Andrejic, N.; Gunjić, I.; Virić, V.; Palibrk, A.; Lee, H.; Peric, S. Secondary Findings in 443 Exome Sequencing Data. Ann. Hum. Genet. 2024, ahg.12586. [Google Scholar] [CrossRef] [PubMed]
  33. Huang, Y.; Liu, B.; Shi, J.; Zhao, S.; Xu, K.; Sun, L.; Chen, N.; Tian, W.; Zhang, J.; Wu, N. Landscape of Secondary Findings in Chinese Population: A Practice of ACMG SF v3.0 List. J. Pers. Med. 2022, 12, 1503. [Google Scholar] [CrossRef] [PubMed]
  34. Jensson, B.O.; Arnadottir, G.A.; Katrinardottir, H.; Fridriksdottir, R.; Helgason, H.; Oddsson, A.; Sveinbjornsson, G.; Eggertsson, H.P.; Halldorsson, G.H.; Atlason, B.A.; et al. Actionable Genotypes and Their Association with Life Span in Iceland. N. Engl. J. Med. 2023, 389, 1741–1752. [Google Scholar] [CrossRef]
  35. Martone, S.; Buonagura, A.T.; Marra, R.; Rosato, B.E.; Del Giudice, F.; Bonfiglio, F.; Capasso, M.; Iolascon, A.; Andolfo, I.; Russo, R. Clinical Exome-Based Panel Testing for Medically Actionable Secondary Findings in a Cohort of 383 Italian Participants. Front. Genet. 2022, 13, 956723. [Google Scholar] [CrossRef]
  36. Georgiou, I.; Makis, A.; Chaidos, A.; Bouba, I.; Hatzi, E.; Kranas, V.; Zilidis, C.; Bourantas, K.L. Distribution and Frequency of β -thalassemia Mutations in Northwestern and Central Greece. Eur. J. Haematol. 2003, 70, 75–78. [Google Scholar] [CrossRef]
  37. De Sanctis, V.; Kattamis, C.; Canatan, D.; Soliman, A.T.; Elsedfy, H.; Karimi, M.; Daar, S.; Wali, Y.; Yassin, M.; Soliman, N.; et al. β-Thalassemia Distribution in the Old World: An Ancient Disease Seen from a Historical Standpoint. Mediterr. J. Hematol. Infect. Dis. 2017, 9, e2017018. [Google Scholar] [CrossRef]
  38. Kwak, S.H.; Chae, J.; Choi, S.; Kim, M.J.; Choi, M.; Chae, J.-H.; Cho, E.; Hwang, T.J.; Jang, S.S.; Kim, J.-I.; et al. Findings of a 1303 Korean Whole-Exome Sequencing Study. Exp. Mol. Med. 2017, 49, e356. [Google Scholar] [CrossRef]
  39. Gordon, A.S.; Zouk, H.; Venner, E.; Eng, C.M.; Funke, B.H.; Amendola, L.M.; Carrell, D.S.; Chisholm, R.L.; Chung, W.K.; Denny, J.C.; et al. Frequency of Genomic Secondary Findings among 21,915 eMERGE Network Participants. Genet. Med. 2020, 22, 1470–1477. [Google Scholar] [CrossRef]
  40. Brunfeldt, M.; Kaare, M.; Saarinen, I.; Koskenvuo, J.; Kääriäinen, H. Opt-in for Secondary Findings as Part of Diagnostic Whole-exome Sequencing: Real-life Experience from an International Diagnostic Laboratory. Mol. Gen. Gen. Med. 2023, 11, e2180. [Google Scholar] [CrossRef]
  41. Husser, D.; Ueberham, L.; Jacob, J.; Heuer, D.; Riedel-Heller, S.; Walker, J.; Hindricks, G.; Bollmann, A. Prevalence of Clinically Apparent Hypertrophic Cardiomyopathy in Germany-An Analysis of over 5 Million Patients. PLoS ONE 2018, 13, e0196612. [Google Scholar] [CrossRef] [PubMed]
  42. Miltiadous, G.; Elisaf, M.; Bairaktari, H.; Xenophontos, S.L.; Manoli, P.; Cariolou, M.A. Characterization and Geographic Distribution of the Low Density Lipoprotein Receptor (LDLR) Gene Mutations in Northwestern Greece. Hum. Mutat. 2001, 17, 432–433. [Google Scholar] [CrossRef] [PubMed]
  43. Diakou, M.; Miltiadous, G.; Xenophontos, S.L.; Manoli, P.; Cariolou, M.A.; Elisaf, M. Spectrum of LDLR Gene Mutations, Including a Novel Mutation Causing Familial Hypercholesterolaemia, in North-Western Greece. Eur. J. Intern. Med. 2011, 22, e55–e59. [Google Scholar] [CrossRef] [PubMed]
  44. Nordestgaard, B.G.; Chapman, M.J.; Humphries, S.E.; Ginsberg, H.N.; Masana, L.; Descamps, O.S.; Wiklund, O.; Hegele, R.A.; Raal, F.J.; Defesche, J.C.; et al. Familial Hypercholesterolaemia Is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease: Consensus Statement of the European Atherosclerosis Society. Eur. Heart J. 2013, 34, 3478–3490. [Google Scholar] [CrossRef]
  45. Rizos, C.V.; Elisaf, M.S.; Skoumas, I.; Tziomalos, K.; Kotsis, V.; Rallidis, L.; Garoufi, A.; Athyros, V.G.; Skalidis, E.; Kolovou, G.; et al. Characteristics and Management of 1093 Patients with Clinical Diagnosis of Familial Hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). Atherosclerosis 2018, 277, 308–313. [Google Scholar] [CrossRef]
  46. Rizos, C.V.; Athyros, V.; Bilianou, E.; Chrousos, G.; Garoufi, A.; Kolovou, G.; Kotsis, V.; Rallidis, L.; Skalidis, E.; Skoumas, I.; et al. An Insight into Familial Hypercholesterolemia in Greece: Rationale and Design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). Hormones 2017, 16, 200–204. [Google Scholar] [CrossRef]
  47. Konstantopoulou, I.; Tsitlaidou, M.; Fostira, F.; Pertesi, M.; Stavropoulou, A.; Triantafyllidou, O.; Tsotra, E.; Tsiftsoglou, A.; Tsionou, C.; Droufakou, S.; et al. High Prevalence of BRCA1 Founder Mutations in Greek Breast/Ovarian Families. Clin. Genet. 2014, 85, 36–42. [Google Scholar] [CrossRef]
  48. Papamentzelopoulou, M.; Apostolou, P.; Fostira, F.; Dimitrakakis, C.; Loutradis, D.; Fountzilas, G.; Yannoukakos, D.; Konstantopoulou, I. Prevalence and Founder Effect of the BRCA1 p.(Val1833Met) Variant in the Greek Population, with Further Evidence for Pathogenicity and Risk Modification. Cancer Genet. 2019, 237, 90–96. [Google Scholar] [CrossRef]
  49. Schiffman, J.D.; Fisher, P.G.; Gibbs, P. Early Detection of Cancer: Past, Present, and Future. Cancer Prev. Genet. Epidemiol. 2015, 35, 57–65. [Google Scholar] [CrossRef]
  50. Hedegaard, B.S.; Bork, C.S.; Kanstrup, H.L.; Thomsen, K.K.; Heitmann, M.; Bang, L.E.; Henriksen, F.L.; Andersen, L.J.; Gohr, T.; Mouridsen, M.R.; et al. Genetic Testing Increases the Likelihood of a Diagnosis of Familial Hypercholesterolaemia among People Referred to Lipid Clinics: Danish National Study. Atherosclerosis 2023, 373, 10–16. [Google Scholar] [CrossRef]
  51. Medeiros, A.M.; Bourbon, M. Genetic Testing in Familial Hypercholesterolemia: Is It for Everyone? Curr. Atheroscler. Rep. 2023, 25, 127–132. [Google Scholar] [CrossRef]
Cimb 47 00272 g001
Figure 1. Distribution of primary indications for referral in 280 individuals enrolled in the study.
Figure 1. Distribution of primary indications for referral in 280 individuals enrolled in the study.
Cimb 47 00272 g001
Cimb 47 00272 g002
Figure 2. Distribution of genes from the ACMG’s SF v3.2 list by phenotype and inheritance pattern.
Figure 2. Distribution of genes from the ACMG’s SF v3.2 list by phenotype and inheritance pattern.
Cimb 47 00272 g002
Cimb 47 00272 g003
Figure 3. Distribution of genes from the ACMG’s SF v2.0 (left) and v3.0 (right) list by phenotype and inheritance pattern.
Figure 3. Distribution of genes from the ACMG’s SF v2.0 (left) and v3.0 (right) list by phenotype and inheritance pattern.
Cimb 47 00272 g003
Cimb 47 00272 g004
Figure 4. Age and sex breakdown of our cohort. (Blue: male, Pink: female).
Figure 4. Age and sex breakdown of our cohort. (Blue: male, Pink: female).
Cimb 47 00272 g004
Cimb 47 00272 g005
Figure 5. Distribution of the P/LP variants in the 23 positive participants. None of the individuals carried homozygous or compound heterozygous recessive disease alleles. (Genes in blue: AD, genes in red: AR).
Figure 5. Distribution of the P/LP variants in the 23 positive participants. None of the individuals carried homozygous or compound heterozygous recessive disease alleles. (Genes in blue: AD, genes in red: AR).
Cimb 47 00272 g005
Table 1. Number of carriers and variants in 59, 73, and 81 ACMG genes.
Table 1. Number of carriers and variants in 59, 73, and 81 ACMG genes.
ACMG SF v2.0ACMG SF v3.0ACMG SF v3.2
ADARXLADARXLADARXL
No. of carriers111201215012150
No. of variants111301216012160
Table 2. P/LP variants in AD ACMG-recommended genes. (He: Heterozygous).
Table 2. P/LP variants in AD ACMG-recommended genes. (He: Heterozygous).
GeneConditionTranscriptVariantdbSNP IDACMG
Classification		ZygosityNumber of Carriers
BRCA1Hereditary breast and/or ovarian cancerNM_007294.4c.3700_3704del p.(Val1234Glnfs*8)rs80357609P (PVS1, PP5, PM2)He1
BRCA1Hereditary breast and/or ovarian cancerNM_007294.4c.5497G>A p.(Val1833Met)rs80357268P (PP5, PM1, PM5, PP3, PM2)He1
BRCA2Hereditary breast and/or ovarian cancerNM_000059.4c.8169T>A p.(Asp2723Glu)rs1060502432P (PM1, PM5, PP3, PM2, PP5)He1
LDLRFamilial hypercholesterolemiaNM_000527.5c.81C>G p.(Cys27Trp)rs2228671P (PP5, PP3, PM1, PM5)He1
LDLRFamilial hypercholesterolemiaNM_000527.5c.858C>A p.(Ser286Arg)rs140241383P (PP5, PS1, PM1, PP3)He3
LDLRFamilial hypercholesterolemiaNM_000527.5c.1775G>A p.(Gly592Glu)rs137929307P (PS3, PM5, PP3, PM1, PP5)He2
MSH6Lynch syndrome (Hereditary Nonpolyposis Colorectal Cancer; HNPCC)NM_000179.3c.2653A>T p.(Lys885*)rs587782593P (PVS1, PP5, PM2)He1
MYH7Hypertrophic cardiomyopathyNM_000257.4c.2609G>T p.(Arg870Leu)rs36211715P (PM1, PM5, PP3, PP5, PM2)He1
TTNDilated cardiomyopathyNM_001267550.2c.52903C>T p.(Arg17635*)rs2154197219P (PVS1, PP5, PM2)He1
Table 3. P/LP variants in AR ACMG-recommended genes. (He: Heterozygous).
Table 3. P/LP variants in AR ACMG-recommended genes. (He: Heterozygous).
GeneConditionTranscriptVariantdbSNP IDACMG
Classification		ZygosityNumber of
Carriers
ATP7BWilson diseaseNM_000053.4c.2304dup p.(Met769Hisfs*26)rs137853287P (PVS1, PP5, PM2)He1
GAAPompe diseaseNM_000152.5c.-32-13T>G p.?rs386834236P (PVS1, PM3, PP4)He2
GAAPompe diseaseNM_000152.5c.1465G>A p.(Asp489Asn)rs398123169P (PP5, PM5, PP3, PM1, PM2)He1
HFEHereditary hemochromatosisNM_000410.4c.845G>A p.(Cys282Tyr)rs1800562P (PS3, PS1, PP5, BP1)He4
MUTYHMUTYH-associated polyposis (MAP)NM_001048174.2/
NM_001128425.2		c.1103G>A p.(Gly368Asp)/c.1187G>A p.(Gly396Asp)rs36053993P (PP5, PP3, PS3, PM5, PP2)He8
Table 4. Gene carrier rates and at-risk couple rates of recessive genes.
Table 4. Gene carrier rates and at-risk couple rates of recessive genes.
GeneNumber of CarriersGene Carrier RateAt-Risk Couple Rate
ATP7B10.00360.000013
GAA30.01070.000115
HFE40.01430.000204
MUTYH80.02860.000818
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kostoulas, C.; Sesse, A.; Bouba, I.; Konitsiotis, S.; Markoula, S.; Georgiou, I. Secondary Findings from Exome Sequencing of a Greek Cohort. Curr. Issues Mol. Biol. 2025, 47, 272. https://doi.org/10.3390/cimb47040272

AMA Style

Kostoulas C, Sesse A, Bouba I, Konitsiotis S, Markoula S, Georgiou I. Secondary Findings from Exome Sequencing of a Greek Cohort. Current Issues in Molecular Biology. 2025; 47(4):272. https://doi.org/10.3390/cimb47040272

Chicago/Turabian Style

Kostoulas, Charilaos, Athanasia Sesse, Ioanna Bouba, Spyridon Konitsiotis, Sofia Markoula, and Ioannis Georgiou. 2025. "Secondary Findings from Exome Sequencing of a Greek Cohort" Current Issues in Molecular Biology 47, no. 4: 272. https://doi.org/10.3390/cimb47040272

APA Style

Kostoulas, C., Sesse, A., Bouba, I., Konitsiotis, S., Markoula, S., & Georgiou, I. (2025). Secondary Findings from Exome Sequencing of a Greek Cohort. Current Issues in Molecular Biology, 47(4), 272. https://doi.org/10.3390/cimb47040272

Article Metrics

Back to TopTop